Fiera Capital Corp Has $81.32 Million Stock Holdings in Colgate-Palmolive Company $CL

Fiera Capital Corp boosted its position in shares of Colgate-Palmolive Company (NYSE:CL) by 14.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,017,238 shares of the company’s stock after purchasing an additional 130,180 shares during the period. Fiera Capital Corp owned 0.13% of Colgate-Palmolive worth $81,318,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Westside Investment Management Inc. lifted its holdings in shares of Colgate-Palmolive by 85.5% during the 2nd quarter. Westside Investment Management Inc. now owns 282 shares of the company’s stock valued at $26,000 after buying an additional 130 shares during the last quarter. Vermillion & White Wealth Management Group LLC raised its position in Colgate-Palmolive by 86.1% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 335 shares of the company’s stock valued at $30,000 after acquiring an additional 155 shares in the last quarter. Copia Wealth Management acquired a new stake in Colgate-Palmolive in the third quarter valued at approximately $29,000. Cloud Capital Management LLC bought a new stake in Colgate-Palmolive in the third quarter worth approximately $30,000. Finally, MTM Investment Management LLC acquired a new position in shares of Colgate-Palmolive during the 2nd quarter worth $39,000. 80.41% of the stock is owned by institutional investors and hedge funds.

Colgate-Palmolive Stock Down 1.7%

NYSE CL opened at $93.93 on Friday. Colgate-Palmolive Company has a twelve month low of $74.54 and a twelve month high of $100.18. The stock has a market cap of $75.71 billion, a PE ratio of 35.85, a PEG ratio of 4.31 and a beta of 0.29. The firm has a 50-day simple moving average of $85.28 and a 200 day simple moving average of $82.19. The company has a debt-to-equity ratio of 5.90, a quick ratio of 0.27 and a current ratio of 0.42.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings results on Friday, January 30th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.91 by $0.04. Colgate-Palmolive had a return on equity of 353.72% and a net margin of 10.45%.The firm had revenue of $5.23 billion during the quarter, compared to analysts’ expectations of $5.13 billion. During the same quarter in the prior year, the firm posted $0.91 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. On average, research analysts forecast that Colgate-Palmolive Company will post 3.75 EPS for the current year.

Colgate-Palmolive Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, February 13th. Shareholders of record on Wednesday, January 21st were paid a dividend of $0.52 per share. The ex-dividend date was Wednesday, January 21st. This represents a $2.08 dividend on an annualized basis and a yield of 2.2%. Colgate-Palmolive’s payout ratio is currently 79.39%.

Insider Buying and Selling at Colgate-Palmolive

In related news, CFO Stanley J. Sutula III sold 97,843 shares of the stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $94.27, for a total value of $9,223,659.61. Following the completion of the transaction, the chief financial officer owned 55,310 shares of the company’s stock, valued at $5,214,073.70. This represents a 63.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John Hazlin sold 20,989 shares of Colgate-Palmolive stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $94.25, for a total value of $1,978,213.25. Following the sale, the insider directly owned 17,645 shares in the company, valued at $1,663,041.25. The trade was a 54.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 184,683 shares of company stock worth $17,486,693. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. The Goldman Sachs Group reissued a “buy” rating and set a $94.00 target price on shares of Colgate-Palmolive in a research report on Saturday, January 31st. Piper Sandler raised their price objective on Colgate-Palmolive from $88.00 to $96.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Morgan Stanley upped their target price on Colgate-Palmolive from $87.00 to $100.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Rothschild & Co Redburn set a $93.00 price target on Colgate-Palmolive in a report on Friday, February 13th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Colgate-Palmolive from $83.00 to $90.00 and gave the stock a “hold” rating in a research note on Monday, February 2nd. Eleven analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.38.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.